Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) hit a new 52-week low during trading on Wednesday . The company traded as low as C$0.67 and last traded at C$0.70, with a volume of 15145 shares. The stock had previously closed at C$0.70.
Oncolytics Biotech Price Performance
The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The business has a 50 day moving average of C$0.95 and a 200 day moving average of C$1.24. The company has a market cap of C$57.03 million, a PE ratio of -2.06 and a beta of 1.35.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
- Five stocks we like better than Oncolytics Biotech
- What Does Downgrade Mean in Investing?
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Are Tariffs Threatening Disney’s Comeback Story?
- How to Invest in the Best Canadian Stocks
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
